Effectiveness of botulinum toxin A in treatment of refractory erythromelalgia  by Lin, Kuan-Hsiang et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 76 (2013) 296e298
www.jcma-online.comCase Report
Effectiveness of botulinum toxin A in treatment of refractory
erythromelalgia
Kuan-Hsiang Lin a,b,*, Shuu-Jiun Wang a,b, Jong-Ling Fuh a,b, Shih-Pin Chen a,b
aDepartment of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
bFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
Received August 1, 2011; accepted January 11, 2012AbstractErythromelalgia is characterized by intense burning pain, erythema, and heat in affected areas after precipitating factors such as warm
temperature or stress. It is refractory to treatment in some situations. We describe a woman with adenosquamous cell carcinoma of the lung and
medically refractory erythromelalgia. The symptoms of erythromelalgia presented as refractory to any medical treatment. Due to the unre-
sponsive nature of her condition, botulinum toxin type A (onabotulinumtoxin A) was injected over both of her cheeks, periodically for six cycles.
Her symptoms responded dramatically to subcutaneous and intradermal injection of botulinum toxin type A. Repetitive injection demonstrated
consistent and reproducible responses, and the efficacy was maintained for approximately 1 month. No adverse effects or complications were
noted. Botulinum toxin type A might be safe and effective as an alternative treatment for refractory erythromelalgia, but further large-scale
studies are required.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Erythromelalgia is a small-fiber neuropathy1 characterized
by intense burning pain, erythema, and warmth in the affected
areas.2 Symptoms are triggered by heat or sunlight exposure,
and can be alleviated by cooling of the affected area. Treat-
ment for this disorder has proven difficult and involves mul-
tiple approaches. We describe a patient with erythromelalgia
who was medically refractory but responded dramatically to
onabotulinumtoxin A injection.
2. Case report
A 58-year-old housewife had suffered intermittent hot
flushing and burning pain over her face and all four limbs* Corresponding author. Dr. Kuan-Hsiang Lin, Department of Neurology,
Neurological Institute, Taipei Veterans General Hospital, 201, Section 2, Shih-
Pai Road, Taipei 112, Taiwan, ROC.
E-mail address: siriuson1202@gmail.com (K.-H. Lin).
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http://dx.doi.org/10.1016/j.jcma.2013.01.003since 2005. The symptoms were exacerbated by warm tem-
peratures, exercise, or sunlight exposure, and relieved by
cooling of the affected area. Physical and neurologic ex-
aminations revealed severe erythema, local heat, and allo-
dynia over the affected areas. Postmenopausal syndrome was
suspected initially, but no satisfactory response to hormone
therapy was noted. Rosacea had also been considered, but
there was no patient response to tetracycline and predni-
solone.
A full diagnostic work-up, including assessment of thyroid
function, hepatitis C testing, plasma catecholamine, urine 5-
hydroxyindoleacetic acid, and vanillylmandelic acid levels,
as well as autoimmune profiles including antinuclear anti-
body, double-stranded DNA, complements, immunoelec-
trophoresis, cryoglobulin, rheumatic factor, anti-SS-A/SS-B,
and anti-Jo-1 antibody were all unrevealing. Nerve conduc-
tion studies were normal. A skin biopsy found decreased
intraepidermal nerve fiber density (5.23 fibers/mm) (Fig. 1A).
The patient was diagnosed with erythromelalgia. In 2009, she
was then diagnosed with adenosquamous cell carcinoma ofhinese Medical Association. All rights reserved.
Fig. 1. Photographs of the patient’s erythromelalgia during the course of treatment and the skin biopsy. (A) Skin biopsies were immunostained with antiprotein
gene product 9.5 (PGP9.5). Epidermal innervation was reduced, with only some visible intraepidermal nerves (arrow). (B) Pretreatment. The patient suffered
severe painful erythema of her face. (C) After treatment with the first subcutaneous injection of onabotulinumtoxin A. Facial flushing improved dramatically. (D)
After treatment with the fourth injection of onabotulinumtoxin A. The improvement was still significant. The patient was wearing a hat because she felt
embarrassed by her chemotherapy-related alopecia. (E) Pretreatment. Erythema of both hands. (F) Post-chemotherapy. There was no notable difference in the
erythema of the hands.
297K.-H. Lin et al. / Journal of the Chinese Medical Association 76 (2013) 296e298the lung. She underwent surgery and chemotherapy with
paclitaxel and cisplatin. There was no tumor recurrence until
August 2010.
The patient’s symptoms of erythromelalgia exacerbated and
became excruciating [verbal numeric scale (VNS) 10/10] from
January, 2010 (Fig. 1B and E). Temporary relief of symptoms
was achieved by immersion of her face in ice water even
during the cold winter months. Treatments including escita-
lopram, propranolol, alprazolam, gabapentin, aspirin, pred-
nisolone, amitriptyline, venlafaxine, duloxetine, mexiletine, or
combinations of these drugs were all ineffective. Given the
refractoriness of symptoms and the nature of the disease, the
patient asked for potential off-label therapeutic choices for
neuropathic pain.
Based on pre-existing evidence for botulinum toxin type
A in the treatment of neuropathic pain3 and one successful
experience in treating idiopathic facial flushing,4 we con-
sidered that botulinum toxin A injection might be effective
in reducing or even eradicating her symptoms. After thor-
ough discussion with the patient about the treatment para-
digms and potential adverse effects, she decided to receive
the treatment and provided written informed consent. Bot-
ulinum toxin type A (onabotulinumtoxin A) injection was
then administered in an effort to relieve the patient from her
substantial suffering.
Initially, the patient received 12.5 U of onabotulinumtoxin
A in 10 locations (1 cm2 per grid) on each cheek subcutane-
ously. At 1 week postinjection, the improvement in facial
flushing and pain was remarkable (VNS 3/10) (Fig. 1C). Nofurther medication was needed. The symptoms relapsed 1
month later after intense sunlight exposure. The patient
received two further injections at twice the dose given in the
initial treatment, which effectively abated her symptoms (VNS
0e2/10) for 4e6 weeks. However, metastatic lung cancer was
noted in August 2010. She received surgery and another
course of chemotherapy. The fourth injection of onabotuli-
numtoxin A intradermally (50 U on each cheek) was provided
in September 2010. Her symptoms improved greatly, which
lasted for 2 months (Fig. 1D). To prevent the development of
antibotulinum toxin antibodies, the interinjection interval was
prolonged to 3 months for subsequent injections. The patient
tolerated all the therapeutic procedures well. A total of six
cycles of onabotulinumtoxin A injection was administered. No
adverse effects or complications were noted during the sub-
sequent 1.5-year therapeutic course.
3. Discussion
Our patient fulfilled the diagnostic criteria of eryth-
romelalgiadburning extremity pain, pain aggravated by
warming, pain relieved by cooling, erythema of the affected
skin, and increased temperature of the affected skin.1 The skin
biopsy from our patient revealed reduced intraepidermal nerve
fiber density (5.23 fibers/mm), which was also consistent with
prior studies.1,5
We hypothesized that the burning pain and allodynia
associated with erythromelalgia were essentially neuropathic
pain, and the erythema and local heat were induced by
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reportedly effective in neuropathic pain,3 and we extrapolated
that these results could benefit our patient. The effectiveness
might be mediated through an inhibition of peripheral and
central sensitization by blocking the release of proin-
flammatory neurotransmitters, such as calcitonin gene-related
peptide, substance P, and glutamate, etc.4,6 Recent studies
modeling neuropathic pain with a local injection of capsaicin
provide circumstantial support.7
In our study, we used a VNS, which is a well-validated and
reliable rating scale for pain, to evaluate the efficacy of the
onabotulinumtoxin A injection.8 The other objective index
was the change in skin color, which appeared in concordance
with the pain, as illustrated in Fig. 1. Transcutaneous tissue
oximetry and laser Doppler flowmetry are more objective as-
sessments for the microcirculation and are expected to provide
more information9; however, these tools were not available in
our clinical practice.
Based on the time course, electrodiagnostic study, and
histopathology, chemotherapy-related peripheral neuropathy is
not likely the culprit for our patient’s symptoms.10 Treatment
for recurrent tumor might contribute to the prolonged remis-
sion, but could not explain the responsiveness of prior ona-
botulinumtoxin A injections. In addition, the noninjected
hands showed no obvious improvement after chemotherapy
(Fig. 1F).
We proposed that onabotulinumtoxin A might serve as an
alternative approach for patients with refractory eryth-
romelalgia. Further randomized trials are needed to systemi-
cally assess the efficacy and safety of onabotulinumtoxin A in
treating refractory erythromelalgia.Acknowledgments
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